Albert Bourla: 2025 was a very good year for Pfizer Inc. I'm very pleased with strong execution to deliver and, frankly, overdeliver on our financial commitments. If successful, we will substantially ...

Exhibit 99.1 Operating and Financial Review DÜSSELDORF, GERMANY - February 3, 2026 – trivago N.V. (NASDAQ: TRVG) (the “Company”, “we,” “us,” “our,” or “trivago,”) announced financial results for the ...

Good day, everyone, and welcome to Pfizer's Fourth Quarter 2025 Earnings Conference Call. Today's call is being recorded. At ...

Cell-Based Assays are expanding post-pandemic, driven by new tech enabling comprehensive cell function measurements. They're pivotal in biotech, with growth fueled by advancements in genomics and ...